Fixed‑Duration Venetoclax After RBAC Improves 2‑Year PFS in High‑Risk Older Mantle Cell Lymphoma: Final Results of the FIL_V‑RBAC Phase 2 Study
Posted inHematology-Oncology news

Fixed‑Duration Venetoclax After RBAC Improves 2‑Year PFS in High‑Risk Older Mantle Cell Lymphoma: Final Results of the FIL_V‑RBAC Phase 2 Study

In a multicentre, risk‑adapted phase 2 trial, adding fixed‑duration venetoclax after rituximab‑bendamustine‑cytarabine (RBAC) produced a 2‑year progression‑free survival of 60% in older patients with high‑risk mantle cell lymphoma (MCL). Toxicities were manageable, neutropenia was most common, and one treatment‑related death occurred.
Nationwide China Study Reveals Age-Specific Burden and Survival Gaps in Acute Leukaemia: Good Outcomes for Children and APL; Poor Prognosis in Older Adults
Posted inHematology-Oncology news Oncology

Nationwide China Study Reveals Age-Specific Burden and Survival Gaps in Acute Leukaemia: Good Outcomes for Children and APL; Poor Prognosis in Older Adults

A large linkage of Chinese national registries (628.4 million population) estimates 43,275 acute leukaemia cases in 2019, describes age-specific incidence peaks in early childhood and older age, reports major survival gains for children and APL, and highlights dismal outcomes for patients ≥60 years.
Neoadjuvant Chidamide plus Anthracycline–Taxane Chemotherapy Yields a 35% RCB 0–I Rate in HR+/HER2– Breast Cancer: Early Phase 2 Results from MUKDEN 05
Posted innews Oncology

Neoadjuvant Chidamide plus Anthracycline–Taxane Chemotherapy Yields a 35% RCB 0–I Rate in HR+/HER2– Breast Cancer: Early Phase 2 Results from MUKDEN 05

In a multicentre phase 2 single-arm trial, oral chidamide added to standard epirubicin–cyclophosphamide followed by docetaxel produced an RCB 0–I rate of 35.2% in stage II–III HR+/HER2– breast cancer, with high rates of grade 3–4 neutropenia but no treatment-related deaths.
Most Adolescents and Young Adults with Solid Tumours Reach Near-Normal 5-Year Survival Within Four Years — Implications for ‘Right to be Forgotten’ Policies
Posted innews Oncology Public Health

Most Adolescents and Young Adults with Solid Tumours Reach Near-Normal 5-Year Survival Within Four Years — Implications for ‘Right to be Forgotten’ Policies

Population-based Dutch data show that AYA survivors of most solid malignancies achieve five-year conditional relative survival >95% by four years post-diagnosis, supporting reconsideration of blanket 10‑year disclosure periods in Right to Be Forgotten laws.
Aducanumab Removes Superficial Cortical Amyloid but Associates with Local Vascular Injury and ARIA: Clinicopathological Evidence from a Retrospective Case–Control Study
Posted inNeurology news

Aducanumab Removes Superficial Cortical Amyloid but Associates with Local Vascular Injury and ARIA: Clinicopathological Evidence from a Retrospective Case–Control Study

Autopsy of aducanumab-treated Alzheimer’s cases shows preferential clearance of superficial layer I amyloid, PET Centiloid reductions, and ARIA-associated microvascular pathology, implicating perivascular amyloid removal and vessel injury as mechanisms that inform monitoring and therapy design.
Tỷ lệ mắc xơ gan ở các nhóm kinh tế và nhân khẩu học tại Thụy Điển: Một nghiên cứu quần thể dựa trên đăng ký và bối cảnh toàn cầu
Posted innews

Tỷ lệ mắc xơ gan ở các nhóm kinh tế và nhân khẩu học tại Thụy Điển: Một nghiên cứu quần thể dựa trên đăng ký và bối cảnh toàn cầu

Bài đánh giá này tổng hợp các bằng chứng về sự gia tăng tỷ lệ mắc xơ gan ở Thụy Điển, nhấn mạnh sự chênh lệch kinh tế xã hội rõ rệt, đặc biệt là trong xơ gan liên quan đến bệnh gan do rượu (ALD) và bệnh gan mỡ liên quan đến rối loạn chuyển hóa (MASLD), với những tác động rộng lớn hơn đối với các nước có thu nhập cao trong việc phòng ngừa và phát hiện sớm.
IL‑10–Armored anti‑CD19 CAR T Cells for R/R B‑ALL: Promising Phase 1 Safety Signals and a New Strategy to Tame Inflammatory Toxicity
Posted inHematology-Oncology news

IL‑10–Armored anti‑CD19 CAR T Cells for R/R B‑ALL: Promising Phase 1 Safety Signals and a New Strategy to Tame Inflammatory Toxicity

A phase 1, single‑arm study evaluated IL‑10–expressing anti‑CD19 CAR T cells in relapsed/refractory B‑ALL, reporting feasibility and encouraging safety signals suggesting attenuated inflammatory toxicity while preserving anti‑leukemic activity. Larger controlled studies are needed to confirm benefit and infectious risk.
Preoperative PAXG Improves Event‑Free Survival over mFOLFIRINOX in Resectable and Borderline Resectable Pancreatic Cancer: First Randomisation Results from PACT‑21 CASSANDRA
Posted innews Oncology

Preoperative PAXG Improves Event‑Free Survival over mFOLFIRINOX in Resectable and Borderline Resectable Pancreatic Cancer: First Randomisation Results from PACT‑21 CASSANDRA

In the multicentre phase 3 PACT‑21 CASSANDRA trial, preoperative PAXG significantly prolonged event‑free survival versus mFOLFIRINOX in resectable and borderline resectable pancreatic ductal adenocarcinoma, with comparable high‑grade toxicity and overall tolerability.
Single-dose Cervarix induces durable seropositivity but fails HPV‑16 GMC non-inferiority versus three-dose Gardasil-4: implications from the PRIMAVERA immunobridging trial
Posted inInfectious Diseases news Public Health

Single-dose Cervarix induces durable seropositivity but fails HPV‑16 GMC non-inferiority versus three-dose Gardasil-4: implications from the PRIMAVERA immunobridging trial

PRIMAVERA immunobridging shows single-dose Cervarix induces near-universal seropositivity at 36 months and non-inferior HPV-18 antibodies versus three-dose Gardasil-4, but HPV-16 antibody GMCs were lower; results inform but do not yet support regulatory single-dose approval.
One in Three Head and Neck Cancer Survivors Still Have Supportive Care Needs at Five Years — Fear of Recurrence and Pain Drive Long-Term Demand
Posted innews Oncology Otorhinolaryngology

One in Three Head and Neck Cancer Survivors Still Have Supportive Care Needs at Five Years — Fear of Recurrence and Pain Drive Long-Term Demand

Longitudinal data from 403 head and neck cancer survivors show that while information and health-system needs decline between years 2 and 5, one-third report at least one moderate-to-high unmet supportive care need at year 5—notably fatigue and dry mouth—with fear of cancer recurrence and ongoing analgesic use being the strongest correlates.
Half of Long‑Term Head and Neck Cancer Survivors Report Unmet Supportive Care Needs — A Multinational Cohort Highlights Clinical and System Drivers
Posted innews Oncology Otorhinolaryngology

Half of Long‑Term Head and Neck Cancer Survivors Report Unmet Supportive Care Needs — A Multinational Cohort Highlights Clinical and System Drivers

A multinational cross‑sectional study of 1,097 head and neck cancer survivors >5 years after diagnosis found that ~50% report moderate‑to‑high unmet supportive care needs, driven by HNC‑specific, psychological and physical/daily living concerns and associated with personal, clinical, lifestyle and health‑system factors.
Dutch Nationwide Registry Shows Large Health-System Burden and Early Progression Risk in Advanced Cutaneous Squamous Cell Carcinoma
Posted inDermatology news Oncology

Dutch Nationwide Registry Shows Large Health-System Burden and Early Progression Risk in Advanced Cutaneous Squamous Cell Carcinoma

The Dutch Keratinocyte Cancer Collaborative (DKCC) provides the first nationwide longitudinal real-world dataset of advanced cutaneous squamous cell carcinoma (CSCC), estimating that 8% of CSCC are locally advanced and demonstrating short median times to recurrence or metastasis, substantial resource needs, and meaningful proportions of untreated metastatic episodes.